XML 60 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies, Accrued Expenses (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Accrued Expenses [Abstract]    
Incentive and other compensation costs $ 650,768 $ 1,082,606
Clinical trial costs 354,762 276,141
Director fees 70,000 60,210
Franchise taxes 0 12,160
Other 75,519 13,179
Accrued expenses $ 1,151,049 $ 1,444,296